Compare British American Tobacco PLC (BTI) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Davita Inc — how do they compare? British American Tobacco PLC trades at $57 (market cap $122.36B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: British American Tobacco PLC is far larger — about 10.8× Davita Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| BTI | DVA | |
|---|---|---|
Market Cap | $122.36B | $11.38B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $240.96 |
52-Week Low | $50.39 | $103.87 |
Enterprise Value | $166.31B | $24.10B |
Dividend Yield | 5.88% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
